Mereo Biopharma Group PLC
NASDAQ:MREO
Intrinsic Value
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. [ Read More ]
The intrinsic value of one MREO stock under the Base Case scenario is 0.67 USD. Compared to the current market price of 3 USD, Mereo Biopharma Group PLC is Overvalued by 78%.
Valuation Backtest
Mereo Biopharma Group PLC
Run backtest to discover the historical profit from buying and selling MREO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Mereo Biopharma Group PLC's business.
What risks and challenges
does Mereo Biopharma Group PLC face in the near future?
Summarize the latest earnings report
of Mereo Biopharma Group PLC.
Provide P/E
for Mereo Biopharma Group PLC and its competitors.
Balance Sheet Decomposition
Mereo Biopharma Group PLC
Current Assets | 54.2m |
Cash & Short-Term Investments | 42.1m |
Receivables | 10.7m |
Other Current Assets | 1.4m |
Non-Current Assets | 26.4m |
PP&E | 1.6m |
Intangibles | 24.8m |
Current Liabilities | 17.5m |
Accounts Payable | 1.9m |
Accrued Liabilities | 4.8m |
Other Current Liabilities | 10.8m |
Non-Current Liabilities | 5.4m |
Long-Term Debt | 4.6m |
Other Non-Current Liabilities | 797k |
Earnings Waterfall
Mereo Biopharma Group PLC
Revenue
|
7.1m
GBP
|
Cost of Revenue
|
-1.9m
GBP
|
Gross Profit
|
5.3m
GBP
|
Operating Expenses
|
-36.9m
GBP
|
Operating Income
|
-31.7m
GBP
|
Other Expenses
|
5.6m
GBP
|
Net Income
|
-26.1m
GBP
|
Free Cash Flow Analysis
Mereo Biopharma Group PLC
What is Free Cash Flow?
MREO Profitability Score
Profitability Due Diligence
Mereo Biopharma Group PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Mereo Biopharma Group PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
MREO Solvency Score
Solvency Due Diligence
Mereo Biopharma Group PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Mereo Biopharma Group PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MREO Price Targets Summary
Mereo Biopharma Group PLC
According to Wall Street analysts, the average 1-year price target for MREO is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.
Shareholder Return
MREO Price
Mereo Biopharma Group PLC
Average Annual Return | -37.2% |
Standard Deviation of Annual Returns | 31.75% |
Max Drawdown | -95% |
Market Capitalization | 420.7m USD |
Shares Outstanding | 140 243 400 |
Percentage of Shares Shorted | 2.21% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).
Contact
IPO
Employees
Officers
The intrinsic value of one MREO stock under the Base Case scenario is 0.67 USD.
Compared to the current market price of 3 USD, Mereo Biopharma Group PLC is Overvalued by 78%.